Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Magnaporthe oryzae Probable Xaa-Pro aminopeptidase PEPP (PEPP) CSB-YP392562MPM
CSB-EP392562MPM
CSB-BP392562MPM
CSB-MP392562MPM
CSB-EP392562MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Ubiquinone biosynthesis protein COQ4, mitochondrial (COQ4) CSB-YP392563MPM
CSB-EP392563MPM
CSB-BP392563MPM
CSB-MP392563MPM
CSB-EP392563MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Pentafunctional AROM polypeptide (MGG_01128), partial CSB-YP392564MPM
CSB-EP392564MPM
CSB-BP392564MPM
CSB-MP392564MPM
CSB-EP392564MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae ATP-dependent RNA helicase MAK5 (MAK5), partial CSB-YP392565MPM
CSB-EP392565MPM
CSB-BP392565MPM
CSB-MP392565MPM
CSB-EP392565MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Probable Xaa-Pro aminopeptidase P (AMPP), partial CSB-YP392566MPM
CSB-EP392566MPM
CSB-BP392566MPM
CSB-MP392566MPM
CSB-EP392566MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Extracellular metalloprotease MGG_08041 (MGG_08041) CSB-YP392567MPM
CSB-EP392567MPM
CSB-BP392567MPM
CSB-MP392567MPM
CSB-EP392567MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae WD repeat-containing protein JIP5 (JIP5) CSB-YP392568MPM
CSB-EP392568MPM
CSB-BP392568MPM
CSB-MP392568MPM
CSB-EP392568MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Protein GET1 (GET1), partial CSB-YP392569MPM1
CSB-EP392569MPM1
CSB-BP392569MPM1
CSB-MP392569MPM1
CSB-EP392569MPM1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Pro-apoptotic serine protease NMA111 (NMA111), partial CSB-YP392570MPM
CSB-EP392570MPM
CSB-BP392570MPM
CSB-MP392570MPM
CSB-EP392570MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Mitochondrial distribution and morphology protein 12 (MDM12), partial CSB-YP392571MPM
CSB-EP392571MPM
CSB-BP392571MPM
CSB-MP392571MPM
CSB-EP392571MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae rRNA-processing protein EFG1 (EFG1) CSB-YP392572MPM
CSB-EP392572MPM
CSB-BP392572MPM
CSB-MP392572MPM
CSB-EP392572MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae ATP-dependent RNA helicase ROK1 (ROK1), partial CSB-YP392573MPM
CSB-EP392573MPM
CSB-BP392573MPM
CSB-MP392573MPM
CSB-EP392573MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Nuclear protein localization protein 4 (NPL4), partial CSB-YP392574MPM
CSB-EP392574MPM
CSB-BP392574MPM
CSB-MP392574MPM
CSB-EP392574MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Magnaporthe oryzae Carboxypeptidase Y homolog A (CPYA) CSB-YP392575MPM
CSB-EP392575MPM
CSB-BP392575MPM
CSB-MP392575MPM
CSB-EP392575MPM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ostreococcus lucimarinus Probable alanine--tRNA ligase, chloroplastic (OSTLU_32618), partial CSB-YP392576ODL
CSB-EP392576ODL
CSB-BP392576ODL
CSB-MP392576ODL
CSB-EP392576ODL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ostreococcus lucimarinus S-adenosylmethionine synthase (METK-1) CSB-YP392577ODL
CSB-EP392577ODL
CSB-BP392577ODL
CSB-MP392577ODL
CSB-EP392577ODL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Prosthecochloris vibrioformis UPF0102 protein Cvib_0014 (Cvib_0014) CSB-YP392578PZJ
CSB-EP392578PZJ
CSB-BP392578PZJ
CSB-MP392578PZJ
CSB-EP392578PZJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Prosthecochloris vibrioformis 50S ribosomal protein L35 (rpmI) CSB-YP392579PZJ
CSB-EP392579PZJ
CSB-BP392579PZJ
CSB-MP392579PZJ
CSB-EP392579PZJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Prosthecochloris vibrioformis Threonine--tRNA ligase (thrS), partial CSB-YP392580PZJ
CSB-EP392580PZJ
CSB-BP392580PZJ
CSB-MP392580PZJ
CSB-EP392580PZJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Prosthecochloris vibrioformis Probable tRNA threonylcarbamoyladenosine biosynthesis protein Gcp (gcp) CSB-YP392581PZJ
CSB-EP392581PZJ
CSB-BP392581PZJ
CSB-MP392581PZJ
CSB-EP392581PZJ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>